Prior aspirin users with acute non-ST-elevation coronary syndromes are at increased risk of cardiac events and benefit from enoxaparin

American Heart Journal

Volumn 141, Issue 4, 2001, Pages 566-572

  Santopinto, Jose ^a   Gurfinkel, Enrique P ^b   Torres, Violeta ^a   Marcos, Eduardo ^a   Bozovich, Gerardo E ^b   Mautner, Branco ^b   McCabe, Carolyn H ^c   Antman, Elliott M ^c  

^a Leonidas Lucero Municipal Hospital   (Argentina)

^b HOSPITAL UNIVERSITARIO FUNDACIÓN FAVALORO   (Argentina)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ENOXAPARIN; HEPARIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; ST SEGMENT ELEVATION; TREATMENT OUTCOME;

EID: 0035091718     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhj.2001.113994     Document Type: Article

References (22)

1. The pathogenesis of coronary artery disease and the acute coronary syndromes (1)
2. The pathogenesis of coronary artery disease and the acute coronary syndromes (2)
3. Antithrombotic therapy in cardiac disease: An emerging approach based on pathogenesis and risk
4. Collaborative overview of randomized trials of antiplatelet therapy, I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
5. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease
6. Acute coronary syndromes: Unstable angina and non-Q-wave myocardial infarction
7. A perspective on the potential problems with aspirin as an antithrombotic agent: A comparison of studies in an animal model with clinical trials
8. Two-year follow-up of aspirin responder and aspirin non responder: A pilot-study including 180 post-stroke patients
9. Unexpected, discordant effects of aspirin on platelet reactivity
10. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in non-prior aspirin users: Primary end points analysis from the ATACS trial. Antithrombotic Therapy in Acute Coronary Syndromes Research Group
11. Clinical predictors of in-hospital prognosis in unstable angina: ECLA 3
12. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 11B trial
13. Randomized trial of prophylactic daily aspirin in British male doctors
14. Variations between countries in invasive cardiac procedures and outcomes in patients with suspected unstable angina or myocardial infarction without initial ST elevation: OASIS (Organisation to Assess Strategies for Ischaemic Syndromes) Registry Investigators
15. Specific antithrombins in the context of current treatment for acute coronary syndromes
16. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina: A meta-analysis
17. The Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group: A comparison of low molecular weight heparin with unfractionated heparin for unstable coronary artery disease
18. Guidelines for the diagnosis and management of unstable angina and non-Q-wave myocardial infarction: Proposed revisions. International Cardiology Forum
19. Prior aspirin use in unstable coronary syndromes results in a lower incidence of non-Q-wave MI but a higher rate of medical therapy failure with unfractionated heparin: The aspirin paradox
20. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction [published erratum appears in N Engl J Med 1998; 339:415]
21. Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes
22. Previous aspirin use may attenuate the severity of the manifestations of acute coronary syndromes